News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012
RDX5791, A NON-SYSTEMIC NHE3 INHIBITOR, ALONE OR IN COMBINATION WITH ENALAPRIL, PREVENTS CARDIOVASCULAR AND RENAL DYSFUNCTION IN SALT FED RATS WITH RENAL INSUFFICIENCY Andrew G. Spencer1, Marc Navre1, Craig F. Plato2, Kristin M. Joly2, Kevin Ida2, Eric D. Labonte1, Jeffrey W.
View HTML
Toggle Summary "Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
View HTML
Toggle Summary Ardelyx, Inc. Closes $30M Series B Financing
Ardelyx, Inc. Closes $30M Series B Financing   FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has closed a Series B preferred stock financing of $30.0 million. Participating in the Series B financing are previous investors in the Company, NEA, CMEA and certain
View HTML
Toggle Summary Ardelyx Appoints Mark Kaufmann to Chief Business Officer
FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has appointed Mr. Kaufmann to the newly created position of Chief Business Officer. Mr. Kaufmann’s role will include business and corporate development, licensing, and strategic planning. Mr.
View HTML